Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study
Open Access
- 18 August 2022
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 174, 113-120
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJournal of Clinical Oncology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialThe Lancet Oncology, 2015
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999